RU2012102284A - Топическая композиция, содержащая ибупрофен - Google Patents

Топическая композиция, содержащая ибупрофен Download PDF

Info

Publication number
RU2012102284A
RU2012102284A RU2012102284/15A RU2012102284A RU2012102284A RU 2012102284 A RU2012102284 A RU 2012102284A RU 2012102284/15 A RU2012102284/15 A RU 2012102284/15A RU 2012102284 A RU2012102284 A RU 2012102284A RU 2012102284 A RU2012102284 A RU 2012102284A
Authority
RU
Russia
Prior art keywords
composition
composition according
group
present
concentration selected
Prior art date
Application number
RU2012102284/15A
Other languages
English (en)
Other versions
RU2505291C2 (ru
Inventor
Эрик Тор ФОССЕЛ
Original Assignee
СТРАТЕДЖИК САЙЕНС ЭНД ТЕКНОЛОДЖИЗ, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by СТРАТЕДЖИК САЙЕНС ЭНД ТЕКНОЛОДЖИЗ, ЭлЭлСи filed Critical СТРАТЕДЖИК САЙЕНС ЭНД ТЕКНОЛОДЖИЗ, ЭлЭлСи
Publication of RU2012102284A publication Critical patent/RU2012102284A/ru
Application granted granted Critical
Publication of RU2505291C2 publication Critical patent/RU2505291C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

1. Композиция для топической доставки к коже субъекта, содержащаядонор оксида азота, выбранный из L-аргинина или его производного;неблагоприятную биофизическую среду, включающую ионную соль;полимер для стабилизации, включающий ксантановую камедь;пропиленгликоль;полисорбатное поверхностно-активное вещество, включающее полисорбат 20; иибупрофен и/или соль ибупрофена.2. Композиция по п.1, где композиция является стабильной при воздействии температуры 40ºС в течение времени, выбранного из, по меньшей мере, приблизительно одного дня, по меньшей мере, приблизительно одной недели, и, по меньшей мере, приблизительно 4 недель.3. Композиция по п.1, где композиция представляет собой крем, гель, примочку или трансдермальный пластырь.4. Композиция по п.1, где донор оксида азота присутствует в концентрации, выбранной из группы, включающей, по меньшей мере, приблизительно 0,5 мас.% из расчета на композицию, по меньшей мере, приблизительно 5 мас.% из расчета на композицию, и, по меньшей мере, приблизительно 7 мас.% из расчета на композицию.5. Композиция по п.1, где ионная соль присутствует в концентрации, выбранной из группы, включающей, по меньшей мере, приблизительно 5 мас.% из расчета на композицию, по меньшей мере, приблизительно 7 мас.% из расчета на композицию, и, по меньшей мере, приблизительно 10 мас.% из расчета на композицию.6. Композиция по п.1, где неблагоприятная биофизическая среда включает одну или несколько солей, выбранных из группы, включающей хлорид натрия, холинхлорид, хлорид магния и хлорид кальция.7. Композиция по п.1, где неблагоприятная биофизическая среда имеет ионную силу, выбранную из группы, включающей, по меньшей мере, приб

Claims (18)

1. Композиция для топической доставки к коже субъекта, содержащая
донор оксида азота, выбранный из L-аргинина или его производного;
неблагоприятную биофизическую среду, включающую ионную соль;
полимер для стабилизации, включающий ксантановую камедь;
пропиленгликоль;
полисорбатное поверхностно-активное вещество, включающее полисорбат 20; и
ибупрофен и/или соль ибупрофена.
2. Композиция по п.1, где композиция является стабильной при воздействии температуры 40ºС в течение времени, выбранного из, по меньшей мере, приблизительно одного дня, по меньшей мере, приблизительно одной недели, и, по меньшей мере, приблизительно 4 недель.
3. Композиция по п.1, где композиция представляет собой крем, гель, примочку или трансдермальный пластырь.
4. Композиция по п.1, где донор оксида азота присутствует в концентрации, выбранной из группы, включающей, по меньшей мере, приблизительно 0,5 мас.% из расчета на композицию, по меньшей мере, приблизительно 5 мас.% из расчета на композицию, и, по меньшей мере, приблизительно 7 мас.% из расчета на композицию.
5. Композиция по п.1, где ионная соль присутствует в концентрации, выбранной из группы, включающей, по меньшей мере, приблизительно 5 мас.% из расчета на композицию, по меньшей мере, приблизительно 7 мас.% из расчета на композицию, и, по меньшей мере, приблизительно 10 мас.% из расчета на композицию.
6. Композиция по п.1, где неблагоприятная биофизическая среда включает одну или несколько солей, выбранных из группы, включающей хлорид натрия, холинхлорид, хлорид магния и хлорид кальция.
7. Композиция по п.1, где неблагоприятная биофизическая среда имеет ионную силу, выбранную из группы, включающей, по меньшей мере, приблизительно 0,25 М и, по меньшей мере, приблизительно 1 М.
8. Композиция по п.1, где неблагоприятная биофизическая среда имеет значение рН, выбранное из группы, включающей, по меньшей мере, приблизительно 9 и меньше чем приблизительно 5.
9. Композиция по п.1, где композиция дополнительно содержит упаковку, содержащую донор оксида азота, причем упаковка выбрана из группы, включающей липосомы, эмульсию коллагена, коллагеновые пептиды и их комбинации.
10. Композиция по п.1, где полимер для стабилизации присутствует в концентрации, выбранной из группы, включающей, по меньшей мере, приблизительно 0,5 мас.% из расчета на композицию и, по меньшей мере, приблизительно 0,8 мас.% из расчета на композицию.
11. Композиция по п.1, где пропиленгликоль присутствует в концентрации, выбранной из группы, включающей, по меньшей мере, приблизительно 3 мас.% из расчета на композицию и, по меньшей мере, приблизительно 5 мас.% из расчета на композицию.
12. Композиция по п.1, где полисорбатное поверхностно-активное вещество присутствует в концентрации, выбранной из группы, включающей, по меньшей мере, приблизительно 1 мас.% из расчета на композицию и, по меньшей мере, приблизительно 2 мас.% из расчета на композицию.
13. Композиция по п.1, где полисорбатное поверхностно-активное вещество имеет формулу
Figure 00000001
14. Композиция по п.13, где сумма w+x+y+z равна 20.
15. Композиция по п.1, где ибупрофен и/или соль ибупрофена присутствуют в концентрации, выбранной из группы, включающей, по меньшей мере, приблизительно 1 мас.% из расчета на композицию, по меньшей мере, приблизительно 3 мас.% из расчета на композицию, по меньшей мере, приблизительно 5 мас.% из расчета на композицию и, по меньшей мере, приблизительно 7 мас.% из расчета на композицию.
16. Способ, включающий нанесение субъекту композиции по п.1.
17. Композиция по п.1, где композиция дополнительно содержит глицерилстеарат, цетиловый спирт, сквалан, изопропилмиристат и олеиновую кислоту.
18. Композиция по п.1, дополнительно содержащая воду в концентрации, выбранной из группы, включающей, по меньшей мере, приблизительно 35 мас.% из расчета на композицию и, по меньшей мере, приблизительно 40 мас.% из расчета на композицию.
RU2012102284/15A 2009-06-24 2009-06-24 Топическая композиция, содержащая ибупрофен RU2505291C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2009/003749 WO2010151240A1 (en) 2009-06-24 2009-06-24 Topical composition containing ibuprofen

Publications (2)

Publication Number Publication Date
RU2012102284A true RU2012102284A (ru) 2013-07-27
RU2505291C2 RU2505291C2 (ru) 2014-01-27

Family

ID=42101947

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012102284/15A RU2505291C2 (ru) 2009-06-24 2009-06-24 Топическая композиция, содержащая ибупрофен

Country Status (15)

Country Link
US (5) US8604081B2 (ru)
EP (2) EP2445492B1 (ru)
KR (2) KR20160017133A (ru)
CN (1) CN102481275B (ru)
AU (1) AU2009348470B2 (ru)
BR (1) BRPI0925099A2 (ru)
CA (1) CA2766354C (ru)
ES (1) ES2607476T3 (ru)
IL (1) IL217154A0 (ru)
IN (1) IN2012DN00516A (ru)
MA (1) MA33454B1 (ru)
MX (1) MX337166B (ru)
NZ (1) NZ597542A (ru)
RU (1) RU2505291C2 (ru)
WO (1) WO2010151240A1 (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US7914814B2 (en) * 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
AU2005216192B2 (en) * 2004-02-23 2010-11-04 Strategic Science & Technologies, Llc Topical delivery of a nitric oxide donor to improve body and skin appearance
EP1737429B1 (en) 2004-04-19 2013-07-17 Strategic Science & Technologies, LLC Transdermal delivery of beneficial substances effected by a high ionic strength environment
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US20110028548A1 (en) * 2004-04-19 2011-02-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
EP2445493A1 (en) 2009-06-24 2012-05-02 Strategic Science & Technologies, LLC Topical composition containing naproxen
US9463158B2 (en) * 2009-06-24 2016-10-11 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
CN102481275B (zh) 2009-06-24 2014-07-23 战略科学技术有限公司 含有布洛芬的表面组合物
CA2798220A1 (en) * 2010-05-05 2011-11-10 Teva Women's Health, Inc. Methods of reducing symptoms in subjects using single dosage forms with tapering release rates
WO2012092525A1 (en) * 2010-12-29 2012-07-05 Strategic Science & Technologies, Llc Cox-2 inhibitors and related compounds, and systems and methods for delivery thereof
US9289495B2 (en) 2010-12-29 2016-03-22 Strategic Science & Technologies, Llc Systems and methods for treatment of allergies and other indications
WO2012092526A1 (en) * 2010-12-29 2012-07-05 Strategic Science & Technologies, Llc Methods and systems for treatment of migraines and other indications
WO2012092527A1 (en) * 2010-12-29 2012-07-05 Strategic Science & Technologies, Llc Delivery of treatments transdermally for fungal infections and other indications
DK2704703T3 (da) 2011-05-03 2019-10-14 Aponia Laboratories Inc Transdermale sammensætninger af ibuprofen og fremgangsmåder til anvendelse deraf
WO2016112201A1 (en) * 2015-01-07 2016-07-14 Strategic Science & Technologies, Llc Techniques and systems for transdermal delivery involving treatment of psoriasis, skin cancer, and other indications
AR102172A1 (es) * 2015-10-05 2017-02-08 Química Luar S R L Una composición farmacéutica bactericida y virucida
US10493049B2 (en) 2016-02-10 2019-12-03 Niracle LLC Applicator-based transdermal drug delivery system for administration of drugs in combination with topical formulations
WO2017214497A1 (en) 2016-06-10 2017-12-14 Clarity Cosmetics Inc. Non-comedogenic hair and scalp care formulations and method for use
CA3082286A1 (en) 2017-12-04 2019-06-13 Johnson & Johnson Consumer Inc. Topical emulsion composition containing nonsteroidal anti-inflammatory drug
US20210308048A1 (en) * 2018-08-01 2021-10-07 Novilla Pharmaceuticals, Inc. Eutectic solvents comprising pharmaceutical agents, and methods of making and use thereof
EP3829541A1 (en) * 2018-08-01 2021-06-09 Novilla Pharmaceuticals, Inc. Systems and methods for delivery of drugs and other substances comprising deep eutectic solvents
CN110870914A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 氨基酸类营养素的应用以及包含它的药物组合物
US11844753B2 (en) 2021-11-08 2023-12-19 Weiyong Li Transdermal drug delivery system for delivering a drug to a patient

Family Cites Families (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5799M (ru) 1966-03-22 1968-03-25
FR5940M (ru) 1966-10-18 1968-04-08
FR1553063A (ru) 1967-11-28 1969-01-10
US3960782A (en) 1974-09-27 1976-06-01 The Procter & Gamble Company Shampoo compositions which impart high luster and manageability to hair
US4185100A (en) 1976-05-13 1980-01-22 Johnson & Johnson Topical anti-inflammatory drug therapy
JPS5753404A (en) 1980-09-17 1982-03-30 Kao Corp External preparation for skin obtained by blending plant extract
GB2094142B (en) 1981-03-06 1984-09-26 Lab For Applied Biology Ltd Injectable solution containing theophylline and a basic amino acid
GB2126868B (en) 1982-09-20 1986-03-19 Ralston Purina Co Method of improving the shelf life of processed meat products
DE3327840C1 (de) 1983-08-02 1984-09-20 Blendax Werke Schneider Co Hautpflegemittel
FR2557452B1 (fr) 1983-12-28 1986-08-14 Roussel Uclaf Nouvelles compositions pour les soins de la peau renfermant de l'huile d'onagre et des traits tissulaires de rate
US4681897A (en) 1984-01-16 1987-07-21 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
JPS60252412A (ja) 1984-05-29 1985-12-13 Nichiban Co Ltd 貼布治療製剤
US4722837A (en) 1984-05-29 1988-02-02 Derma-Cure, Inc. Medicated shampoo composition
US4692462A (en) 1985-03-18 1987-09-08 Menley & James Laboratories, Ltd. Compositions and method of controlling transdermal penetration of topical and systemic agents
US4732892A (en) 1985-07-12 1988-03-22 American Home Products Corporation L-α-amino acids as transdermal penetration enhancers
EP0226332B1 (en) 1985-11-18 1992-03-25 Beecham Group Plc Veterinary compositions
GB8606368D0 (en) 1986-03-14 1986-04-23 Unilever Plc Skin treatment composition
FR2602678B1 (fr) 1986-08-13 1992-06-05 Drouault Guy Composition pharmaceutique aqueuse a base de sels de magnesium, sodium et potassium pour la regulation des circulations locales
US4940456A (en) 1987-02-10 1990-07-10 Dan Sibalis Electrolytic transdermal delivery of proteins
US4885157A (en) 1987-02-13 1989-12-05 Fiaschetti Mary G Dermal cosmetic composition and applications therefor
DE3715576A1 (de) 1987-05-09 1988-11-24 Wella Ag Neue makromolekulare, oberflaechenaktive, quaternaere n-substituierte chitosanderivate sowie kosmetisches mittel auf der basis dieser neuen chitosanderivate
KR900004875Y1 (ko) 1987-10-02 1990-05-31 삼성전자 주식회사 Pip의 수평 윈도우 신호발생 회로
JPH045231Y2 (ru) 1987-12-16 1992-02-14
US5925372A (en) 1987-12-16 1999-07-20 Novartis Corporation Mixed solvent mutually enhanced transdermal therapeutic system
US4871718A (en) 1987-12-29 1989-10-03 Raymond A. Roncari Composition of matter for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair
GB2217595B (en) 1988-04-21 1991-11-20 American Cyanamid Co Antiinflammatory gel
DE3827362A1 (de) 1988-08-12 1990-02-15 Basf Ag Pulvrige, hydrophile theophyllinformulierung und verfahren zur ihrer herstellung
EP0406347A4 (en) 1988-09-30 1991-04-03 Kazuo Watanabe Anti-inflammatory and analgesic compounds, related compositions and methods for preparation and use thereof
US4945901A (en) 1989-03-22 1990-08-07 Burcke Jr Harry J Hand therapy apparatus and method therefor
US5158761A (en) 1989-04-05 1992-10-27 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
US5476852A (en) 1989-05-03 1995-12-19 Janssen Pharmaceutica N.V. Method of topically treating acne vulgaris, hyperkeratotic dermatoses, and photo-aging of the skin
US5028435A (en) 1989-05-22 1991-07-02 Advanced Polymer Systems, Inc. System and method for transdermal drug delivery
JP2761939B2 (ja) 1989-09-04 1998-06-04 株式会社コーセー 水中油型乳化化粧料
PT95564B (pt) 1989-10-17 1997-11-28 Merck & Co Inc Processo para a preparacao de (+)-ibuprofen-d-aminoacido uteis como analgesicos intensificados de ataque acelerado
US5576351A (en) 1989-12-29 1996-11-19 Mcgaw, Inc. Use of arginine as an immunostimulator
EP0441119A3 (en) 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5332758A (en) 1990-07-13 1994-07-26 Kanebo, Ltd. Collagen metabolism ameliorant and its use
US5824658A (en) 1990-09-18 1998-10-20 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
AU651630B2 (en) 1990-11-14 1994-07-28 Pharmacia & Upjohn Company 5-fluoro-2,4,6-pyrimidinetriamine compounds
DE4100975A1 (de) 1991-01-15 1992-07-16 Weuffen Wolfgang Kosmetische oder pharmazeutische zubereitungen zur verbesserung der haarqualitaet und foerderung des haarwachstums
US5210099A (en) 1991-02-11 1993-05-11 American Home Products Corporation Analgesic compositions
WO1992015276A2 (en) 1991-03-01 1992-09-17 Mcginnis, Michael Therapeutic and cosmetic compositions for treatment of skin
ATE157009T1 (de) 1991-03-01 1997-09-15 Atherton Investments Ltd Therapeutische und kosmetische zusammensetzungen zur hautbehandlung
US5498420A (en) 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
DE69202098T2 (de) 1991-05-27 1995-08-17 Fujisawa Pharmaceutical Co N-Pentadecylnicotinat-N-Oxid sowie dieses enthaltendes Haarregenerierendes Mittel.
JP2636118B2 (ja) 1991-09-10 1997-07-30 三省製薬株式会社 育毛剤
US5254331A (en) 1991-09-12 1993-10-19 Chanel, Inc. Skin cream composition
US5215759A (en) 1991-10-01 1993-06-01 Chanel, Inc. Cosmetic composition
US5217652A (en) 1991-10-04 1993-06-08 The Gillette Company Conditioning shampoo
IT1252061B (it) 1991-11-22 1995-05-29 Gentili Ist Spa Composizioni per uso dermatologico e cosmetico
ATE169826T1 (de) 1992-01-21 1998-09-15 Macrochem Corp Iontophoretische verbesserte verabreichung von medikamenten
JP3302995B2 (ja) 1992-04-01 2002-07-15 株式会社ダイゾー エアゾール組成物
US5632981A (en) 1992-08-24 1997-05-27 The United States Of America As Represented By The Department Of Health And Human Services Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
US5405919A (en) 1992-08-24 1995-04-11 The United States Of America As Represented By The Secretary Of Health And Human Services Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders
US5691423A (en) 1992-08-24 1997-11-25 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-bound nitric oxide-nucleophile adducts
KR100271225B1 (ko) 1992-08-31 2000-11-01 후나키 토시유키 안전스위치장치
DK169121B1 (da) 1992-09-09 1994-08-22 Gea Farmaceutisk Fabrik As Antiviralt virksom farmaceutisk olie-i-vand-emulsion indeholdende 9-[(2-hydroxyethoxy)methyl]guanin (acyclovir) eller et salt eller en ester deraf
GB9222772D0 (en) 1992-10-30 1992-12-09 Unilever Plc Cosmetic composition
US5573776A (en) 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
JP3191833B2 (ja) 1993-02-24 2001-07-23 三菱東京製薬株式会社 育毛剤
JPH06287135A (ja) 1993-04-01 1994-10-11 Lion Corp 皮膚外用剤組成物
US5439938A (en) 1993-04-07 1995-08-08 The Johns Hopkins University Treatments for male sexual dysfunction
US5428070A (en) 1993-06-11 1995-06-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production of activity
US5852058A (en) 1993-06-11 1998-12-22 The Board Of Trustees Of The Leland Stanford Junior University Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
US5891459A (en) 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
DE4338793A1 (de) 1993-11-12 1995-05-18 Froelich Juergen C L-Arginin und Analoge als Thrombozytenaggregationshemmer
DE4341000A1 (de) 1993-12-02 1995-06-08 Beiersdorf Ag Verwendung von L-Arginin, L-Ornithin oder L-Citrullin und topischen Zubereitungen mit diesen Stoffen
US5714472A (en) 1993-12-23 1998-02-03 Nestec Ltd. Enternal formulation designed for optimized nutrient absorption and wound healing
GB9409281D0 (en) 1994-05-10 1994-06-29 Svedman Paul Transdermal device
JPH07316075A (ja) 1994-05-26 1995-12-05 Pola Chem Ind Inc 皮膚外用剤
US6190704B1 (en) 1994-09-23 2001-02-20 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Regulation of wound healing by nitric oxide
US5543430A (en) 1994-10-05 1996-08-06 Kaesemeyer; W. H. Method and formulation of stimulating nitric oxide synthesis
US5505958A (en) 1994-10-31 1996-04-09 Algos Pharmaceutical Corporation Transdermal drug delivery device and method for its manufacture
WO1996014083A1 (de) 1994-11-04 1996-05-17 Polymun Scientific Immunbiologische Forschung Gmbh Applikation von sod in liposomen
US5594032A (en) 1994-11-10 1997-01-14 Gonzalez-Cadavid; Nestor F. Amelioration of human erectile dysfunction by treatment with iNOS, inducers of iNOS or iNOS cDNA
US5648101A (en) 1994-11-14 1997-07-15 Tawashi; Rashad Drug delivery of nitric oxide
US5562917A (en) 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5853768A (en) 1995-03-01 1998-12-29 Altadonna; James Topical preparation and method for pain relief
US5654337A (en) 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
US5595753A (en) 1995-04-14 1997-01-21 President And Fellows Of Harvard College Topical formulations and methods for treating hemorrhoidal pain and sphincter and smooth muscle spasm in the gastrointestinal tract
US5643586A (en) 1995-04-27 1997-07-01 Perricone; Nicholas V. Topical compositions and methods for treatment of skin damage and aging using catecholamines and related compounds
US5698738A (en) 1995-05-15 1997-12-16 Board Of Regents, The University Of Texas System N-nitroso-N-substituted hydroxylamines as nitric oxide donors
US5762963A (en) 1995-06-07 1998-06-09 Emory University Method and compositions for controlling oral and pharyngeal pain using capsaicinoids
US5645859A (en) 1995-10-02 1997-07-08 Isp Investments Inc. Process for producing an alpha or beta-hydroxy acid-vinylpyrrolidone polymer, copolymer or graft polymer complex in the form of free-flowing powders having a high acid loading
US5605685A (en) 1995-09-13 1997-02-25 Isp Investments Inc. Non-irritating skin and hair rejuvenating compostion having a pH between 1 and 6.5
US5734080A (en) 1995-09-22 1998-03-31 Anihealth Corporation Reaction product of arginine and p-aminobenzoic acid, cosmetic, and human and animal health compositions thereof
US6036977A (en) 1995-09-29 2000-03-14 L.A.M. Pharmaceutical Corp. Drug preparations for treating sexual dysfunction
FR2740339B1 (fr) 1995-10-26 1997-12-05 Oreal Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
FR2740453B1 (fr) 1995-10-27 1998-01-16 Bieurope Melanges peptidiques, leur preparation et compositions cosmetiques les contenant
JP2681881B2 (ja) 1995-11-24 1997-11-26 ナショナル サイエンス カウンシル 抗ウイルス剤アシクロビルの経皮吸収製剤
US5789442A (en) 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
JPH09208460A (ja) 1996-01-31 1997-08-12 Lion Corp 貼付剤
JP4020989B2 (ja) 1996-03-06 2007-12-12 株式会社ノエビア 血流促進剤及びこれを配合して成る皮膚外用剤
GB9608408D0 (en) 1996-04-23 1996-06-26 Adams Michael A Treatment of erectile dysfunction
US5911980A (en) 1996-06-27 1999-06-15 Macrochem Corporation Lipophilic and amphiphilic or hydrophilic film-forming polymer compositions, and use thereof in topical agent delivery system and method of delivering agents to the skin
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
US20020015713A1 (en) 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
US5891472A (en) 1996-11-19 1999-04-06 Meri Charmyne Russell Treatment of equine laminitis
JPH10167953A (ja) 1996-12-06 1998-06-23 Daicel Chem Ind Ltd 化粧品組成物
US5807957A (en) 1996-12-23 1998-09-15 Macrochem Corporation Cationic film-forming polymer compositions, and use thereof in topical agents delivery system and method of delivering agents to the skin
IL120531A (en) 1997-03-26 2006-12-31 Yissum Res Dev Co Nitric oxide donors and pharmaceutical compositions containing them
FR2762782B1 (fr) 1997-05-05 1999-06-11 Oreal Composition comprenant un milieu de culture de micro-organisme et utilisation
JP4856295B2 (ja) 1997-07-03 2012-01-18 アメリカ合衆国政府 新規な一酸化窒素放出アミジン誘導ジアゼニウムジオレート及びその組成物
US5976566A (en) 1997-08-29 1999-11-02 Macrochem Corporation Non-steroidal antiinflammtory drug formulations for topical application to the skin
US5922332A (en) 1997-09-17 1999-07-13 Fossel; Eric T. Topical delivery of arginine to overcome pain
US7629384B2 (en) 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US6207713B1 (en) 1997-09-17 2001-03-27 Eric T. Fossel Topical and oral delivery of arginine to cause beneficial effects
US5895658A (en) 1997-09-17 1999-04-20 Fossel; Eric T. Topical delivery of L-arginine to cause tissue warming
WO1999013717A1 (en) 1997-09-17 1999-03-25 Strategic Science & Technologies, Inc. A delivery of arginine to cause beneficial effects
US7914814B2 (en) 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US6096759A (en) 1997-09-19 2000-08-01 Georgetown University Method for treating essential hypertension
US5906822A (en) 1997-09-25 1999-05-25 Macrochem Corporation Cationic film-forming polymer compositions, and use thereof in topical agents delivery system and method of delivering agents to the skin
US20040014761A1 (en) 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6046244A (en) 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
GB9801398D0 (en) 1998-01-22 1998-03-18 Anggard Erik E Chemical compounds
KR20010043866A (ko) 1998-06-01 2001-05-25 안쏘니 제이. 버비스카 국소용 경피 치료제
US6103275A (en) 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
US6117872A (en) 1998-06-23 2000-09-12 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of exercise performance by augmenting endogenous nitric oxide production or activity
MXPA00012844A (es) 1998-07-07 2004-05-21 Transdermal Technologies Inc Composiciones para la liberacion transdermica rapida y sin irritacion de agentes farmaceuticamente activos y metodos para formular tales composiciones y liberar los mismos.
DE19830649C2 (de) 1998-07-09 2003-04-10 Lohmann Therapie Syst Lts Topisches Pflaster mit nichtsteroidalen Antirheumatika mit Säuregruppe
DE19831798A1 (de) 1998-07-15 2000-01-27 Mandorlo Investment Gmbh Luxem Mittel zur Pflege und/oder Behandlung von Haut und Gewebe
WO2000024365A1 (en) 1998-10-26 2000-05-04 University Of Massachusetts Treatment of skin with adenosine or adenosine analog
US6261594B1 (en) 1998-11-25 2001-07-17 The University Of Akron Chitosan-based nitric oxide donor compositions
JP2000186028A (ja) 1998-12-21 2000-07-04 Nobuko Koga 化粧品
FR2787996B1 (fr) 1998-12-30 2002-05-10 Dior Christian Parfums Composition cosmetique ou dermatologique contenant un actif stimulant la synthese de la proteine hsp 32 dans la peau et methode de traitement cosmetique
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
EP1161306B1 (en) 1999-03-12 2006-07-26 Mystic Tan, Inc. Misting apparatus for application of coating materials to skin surface
WO2000054773A1 (en) 1999-03-12 2000-09-21 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
US6375672B1 (en) 1999-03-22 2002-04-23 Board Of Trustees Of Michigan State University Method for controlling the chemical and heat induced responses of collagenous materials
FR2794974B1 (fr) 1999-06-16 2001-08-17 Exsymol Sa Composition cosmetique pour l'amincissement a base de l-arginine, d'un analogue de l-arginine ou d'un de leurs derives, applicable par voie topique
CA2384080C (en) 1999-09-07 2012-03-20 Kabushiki Kaisha Soken Skin conditioner
US6558695B2 (en) 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
US6562370B2 (en) 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers
US6602912B2 (en) 2000-06-30 2003-08-05 Dermatrends, Inc. Transdermal administration of phenylpropanolamine
US6582724B2 (en) 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US6719997B2 (en) 2000-06-30 2004-04-13 Dermatrends, Inc. Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers
US6565879B1 (en) 1999-12-16 2003-05-20 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs with hydroxide-releasing agents as skin permeation enhancers
US6586000B2 (en) 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
FR2802414B1 (fr) 1999-12-20 2003-06-27 G Pharm Lab Composition, notamment cosmetique ou dermatologique, contenant des oligosaccharides, son procede de preparation et un procede de traitement cosmetique
DE10003767A1 (de) 2000-01-28 2001-10-04 Beiersdorf Ag Hautfreundliches Wirkstoffpflaster zur transdermalen Verabreichung nichtsteroidaler Antirheumatika
JP2001288068A (ja) 2000-04-06 2001-10-16 Nof Corp 皮膚化粧料
FR2810540B1 (fr) 2000-06-21 2004-04-30 C3D Nouvelles preparations cosmetiques ou hygieniques sous forme de dispersion
JP2002003373A (ja) 2000-06-27 2002-01-09 Shiseido Co Ltd 皮膚外用剤
HUP0002628A2 (en) 2000-07-14 2002-06-29 Keri Pharma Kft Pharmaceutical combinations for treating diabetes
US6538033B2 (en) 2000-08-29 2003-03-25 Huntington Medical Research Institutes Nitric oxide donor compounds
US6468557B1 (en) 2001-01-05 2002-10-22 Alphamed Pharmaceutical Corp. Method for treating infectious viral diseases
JP2004520388A (ja) 2001-01-25 2004-07-08 ザ ジェネラル ホスピタル コーポレーション しわを治療するためのｎｏｓ阻害剤
WO2002087700A1 (en) 2001-04-26 2002-11-07 The Procter & Gamble Company Method, kit and device for the treatment of cosmetic skin conditions
DE10128910A1 (de) 2001-06-15 2002-12-19 Beiersdorf Ag Verwendung von Wirkstoffkombinationen aus Arginin und Ascorbinsäure zur Hautstraffung
JP4563679B2 (ja) 2001-12-06 2010-10-13 デューク ユニバーシティ 形成外科における組織弁壊死の予防
US20030157185A1 (en) 2002-02-08 2003-08-21 Lou Paradise Topical treatment of neuropathy
WO2003072039A2 (en) 2002-02-22 2003-09-04 Essentia Biosystems, Inc. Cosmetic formulations containing l-arginine oligomers
EP1495026A4 (en) 2002-03-20 2008-07-09 Univ Queensland METHOD AND COMPOSITIONS CONTAINING STAIN OXIDE DISPENSERS AND OPIOLD ANALGETICS
WO2003080104A2 (en) 2002-03-22 2003-10-02 Applied Research Systems Ars Holding N.V. Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases
JP2003286129A (ja) 2002-03-27 2003-10-07 Hakugen:Kk 痩身シート材
CA2480832A1 (en) 2002-04-05 2003-10-23 Nitromed, Inc. Nitric oxide donors, compositions and methods of use
RU2229286C2 (ru) * 2002-05-27 2004-05-27 Пятигорская государственная фармацевтическая академия Мазь ибупрофена, приготовленная на полиэтиленоксидной основе, обладающая противовоспалительным действием
JP4419368B2 (ja) 2002-07-25 2010-02-24 小野薬品工業株式会社 プロスタグランジン誘導体およびその誘導体を有効成分として含有する薬剤
US20020168424A1 (en) 2002-07-31 2002-11-14 Dr. Mohsen Shahinpoor Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for glaucoma
IL152486A0 (en) * 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US20050271596A1 (en) * 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof
US7241456B2 (en) 2002-10-25 2007-07-10 Australian Importers Ltd. Formulations for topical delivery of bioactive substances and methods for their use
US9265725B2 (en) * 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
JP2006525945A (ja) 2003-05-16 2006-11-16 美時化学製薬股▲ふん▼有限公司 皮膚を通して投薬される外用組成物
AU2003903037A0 (en) 2003-06-17 2003-07-03 Institute Of Nutraceutical Research Connective tissue derived polypeptides
WO2004112723A2 (en) 2003-06-20 2004-12-29 Ronald Aung-Din Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
US20050069590A1 (en) 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
JP2005200370A (ja) 2004-01-16 2005-07-28 Nikko Chemical Co Ltd 一酸化窒素産生促進剤およびその利用
AU2005216192B2 (en) 2004-02-23 2010-11-04 Strategic Science & Technologies, Llc Topical delivery of a nitric oxide donor to improve body and skin appearance
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US9205062B2 (en) 2004-03-09 2015-12-08 Mylan Pharmaceuticals, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
EP1737429B1 (en) * 2004-04-19 2013-07-17 Strategic Science & Technologies, LLC Transdermal delivery of beneficial substances effected by a high ionic strength environment
US20090105336A1 (en) 2004-04-19 2009-04-23 Strategic Science & Technologies, Llc Beneficial Effects of Increasing Local Blood Flow
US20110028548A1 (en) 2004-04-19 2011-02-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
ITMI20041492A1 (it) 2004-07-23 2004-10-23 Italiano Biochimico Far Maceut Nuovo dispositivo per il rilascio di principi attivi
US20070087977A1 (en) 2004-11-16 2007-04-19 Wendye Robbins Methods and compositions for treating pain
ES2437201T3 (es) 2005-03-03 2014-01-09 Green, Monique Renata Composiciones de geles tópicos
US7442690B2 (en) 2005-03-14 2008-10-28 P & L Enterprise Llc Topical treatment for psoriasis
MX2008003422A (es) * 2005-09-16 2008-03-27 Galderma Res & Dev Composiciones que comprenden al menos un derivado de acido naftoico y al menos un compuesto de tipo polimero de poliuretano o derivados del mismo, procesos de preparacion y composiciones que comprenden al menos un derivado de acido naftoico y al meno
EP1770086A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
WO2007072923A1 (ja) 2005-12-22 2007-06-28 Kowa Company, Ltd. ステロイドの経時的安定性が改善された外用製剤
FR2904549B1 (fr) 2006-08-03 2012-12-14 Sederma Sa Composition comprenant de la sarsasapogenine
EP2054425A1 (en) 2006-08-11 2009-05-06 The University Of Warwick Osmium compounds
CN101534862A (zh) 2006-10-12 2009-09-16 乐敦制药株式会社 用于皮肤的外用制剂
US20100015184A1 (en) 2006-12-13 2010-01-21 Tuel Stephen M Methods of Making Pharmaceutical Components for Customized Drug Products
MX363435B (es) 2007-03-22 2019-03-22 Berg Llc Formulaciones topicas que tienen biodisponibilidad aumentada.
US20080255103A1 (en) * 2007-04-12 2008-10-16 Ballay Pharmaceuticals, Inc. Antihistamine and anti-nausea pharmaceutical compositions for topical application
JP2009196934A (ja) 2008-02-21 2009-09-03 Daiichi Sankyo Co Ltd ニューキノロン系抗菌薬及び乳剤性基剤を含む医薬組成物
US8686040B2 (en) 2008-03-31 2014-04-01 Rdd Pharma Ltd. Method for treating anal pruritis and other perianal disorders
US20100099766A1 (en) 2008-10-16 2010-04-22 Novartis Ag Topical NSAID compositions having sensate component
US8969081B2 (en) 2008-12-10 2015-03-03 The Trustees Of Columbia University In The City Of New York Caudal motor neuron derived from embryonic stem cells under conditions essentially free of any retinoid
PL2210588T3 (pl) * 2008-12-23 2011-09-30 Intendis Gmbh Kompozycje pianotwórcze do leczenia skóry ludzkiej zasadniczo niezawierające aktywnych składników farmaceutycznych
CN105132395A (zh) 2009-03-09 2015-12-09 生物蛋白有限公司 Mirac蛋白
CN102458374A (zh) 2009-05-06 2012-05-16 实验室护肤股份有限公司 包含活性剂-磷酸钙颗粒复合物的皮肤递送组合物及其使用方法
JP2012526840A (ja) 2009-05-13 2012-11-01 プロテイン デリヴァリー ソリューションズ エルエルシー 膜貫通送達のための製剤系
CN102481275B (zh) 2009-06-24 2014-07-23 战略科学技术有限公司 含有布洛芬的表面组合物
US9463158B2 (en) 2009-06-24 2016-10-11 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
EP2445493A1 (en) 2009-06-24 2012-05-02 Strategic Science & Technologies, LLC Topical composition containing naproxen
US20120027876A1 (en) 2010-07-27 2012-02-02 Sara Beth Ford Composition and Method for the Topical Treatment of Dermatitis
WO2012092526A1 (en) 2010-12-29 2012-07-05 Strategic Science & Technologies, Llc Methods and systems for treatment of migraines and other indications
US9289495B2 (en) 2010-12-29 2016-03-22 Strategic Science & Technologies, Llc Systems and methods for treatment of allergies and other indications
WO2012092527A1 (en) 2010-12-29 2012-07-05 Strategic Science & Technologies, Llc Delivery of treatments transdermally for fungal infections and other indications
WO2012092525A1 (en) 2010-12-29 2012-07-05 Strategic Science & Technologies, Llc Cox-2 inhibitors and related compounds, and systems and methods for delivery thereof
WO2012109743A1 (en) 2011-02-18 2012-08-23 Precision Biologic Inc. Methods and compositions relating to coagulation assays

Also Published As

Publication number Publication date
IN2012DN00516A (ru) 2015-08-21
US20140056971A1 (en) 2014-02-27
WO2010151240A1 (en) 2010-12-29
MX2012000047A (es) 2012-04-30
MX337166B (es) 2016-02-15
MA33454B1 (fr) 2012-07-03
EP2445492A1 (en) 2012-05-02
KR101643797B1 (ko) 2016-07-28
ES2607476T3 (es) 2017-03-31
US9457092B2 (en) 2016-10-04
IL217154A0 (en) 2012-02-29
US20110182977A1 (en) 2011-07-28
KR20160017133A (ko) 2016-02-15
RU2505291C2 (ru) 2014-01-27
AU2009348470A1 (en) 2012-02-02
EP2445492B1 (en) 2016-09-28
US9155701B2 (en) 2015-10-13
US8604081B2 (en) 2013-12-10
CA2766354C (en) 2019-08-13
NZ597542A (en) 2014-01-31
CN102481275B (zh) 2014-07-23
CN102481275A (zh) 2012-05-30
AU2009348470B2 (en) 2015-04-02
US9161915B2 (en) 2015-10-20
US20160136281A1 (en) 2016-05-19
US20150366829A1 (en) 2015-12-24
BRPI0925099A2 (pt) 2018-10-16
CA2766354A1 (en) 2010-12-29
KR20120106933A (ko) 2012-09-27
EP3045171A1 (en) 2016-07-20
US20140073697A1 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
RU2012102284A (ru) Топическая композиция, содержащая ибупрофен
JP2014501284A5 (ru)
JP2014504592A5 (ru)
JP2022174292A5 (ru)
KR102706515B1 (ko) 2상 시스템을 구비한 국소 제품
JP2014501283A5 (ru)
JP2011116787A5 (ru)
RU2015122627A (ru) Кожные композиции, содержащие неприродные гигроскопические аминокислоты
JP2014501285A5 (ru)
JP2001026514A (ja) 痩せるための化粧品組成物
CN108113920A (zh) 一种缓释美白复合保湿面霜基质及其制备方法和应用
JPS6110504A (ja) 化粧用組成物
CN106470665B (zh) 具有减少刺激的化妆品组合物
CN105517535A (zh) 水杨酸凝胶
JP6004364B2 (ja) 皮膚外用剤
US6703030B2 (en) Amino fruit acid composition and method for the treatment of skin
JP5423002B2 (ja) 亜鉛を有効成分として含有するコラーゲン合成促進剤
US7241808B2 (en) Composition for treatment of skin and method for stabilizing the composition
JPH1160481A (ja) 皮膚外用剤のイオン導入液
JP2011046690A (ja) 育毛剤組成物
RU2005122467A (ru) Способ химической стабилизации собилизированного ретиноида и водная композиция, полученная этим способом, содержащая по меньшей мере один ретиноид в виде соли
CN114983855B (zh) 一种具有抑制酪氨酸酶活性的复合肽及其制备方法和应用
JP5659407B2 (ja) 経皮吸収促進性皮膚外用剤
WO2016065443A1 (pt) Preparação oral para redução da erosão dentinária, composição oral para redução da erosão dentinária e uso da preparação
KR20210063600A (ko) 피부개선 효과를 갖는 동결건조 패치형 화장료조성물

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20170625